Remus Pharmaceuticals (NSE:REMUS) Property, Plant and Equipment: ₹178 Mil (As of Mar. 2026)


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
61 GF Score
Price ₹739.95
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Property, Plant and Equipment?

Remus Pharmaceuticals NSE:REMUS -1.04% 61 Property, Plant and Equipment is ₹178 Mil as of Mar. 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 61/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Remus Pharmaceuticals's quarterly net PPE increased from Mar. 2025 (₹68 Mil) to Sep. 2025 (₹91 Mil) and increased from Sep. 2025 (₹91 Mil) to Mar. 2026 (₹178 Mil).

Remus Pharmaceuticals's annual net PPE increased from Mar. 2024 (₹49 Mil) to Mar. 2025 (₹68 Mil) and increased from Mar. 2025 (₹68 Mil) to Mar. 2026 (₹178 Mil).


Remus Pharmaceuticals  (NSE:REMUS) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Remus Pharmaceuticals Property, Plant and Equipment Related Terms


Remus Pharmaceuticals Property, Plant and Equipment Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Property, Plant and Equipment Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Property, Plant and Equipment
Get a 7-Day Free Trial 3.09 28.60 48.70 68.40 178.00

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.70 45.57 68.40 90.50 178.00
NSE:REMUS
61GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Property, Plant and Equipment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.

What does a Property, Plant and Equipment of ₹178 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a Property, Plant and Equipment of ₹178 Mil as of Mar. 2026. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Property, Plant and Equipment too high?
Remus Pharmaceuticals' current Property, Plant and Equipment is ₹178 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Property, Plant and Equipment compare to MCK and CAH?
Remus Pharmaceuticals' Property, Plant and Equipment of ₹178 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Property, Plant and Equipment for a Medical Distribution company?
A good Property, Plant and Equipment depends on the Medical Distribution industry context. However, Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Property, Plant and Equipment mean?
A high Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Property, Plant and Equipment is ₹178 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹739.95 — trading 64.3% below its estimated fair value. The current Property, Plant and Equipment is ₹178 Mil. Remus Pharmaceuticals' overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Property, Plant and Equipment calculated?
Property, Plant and Equipment is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Property, Plant and Equipment is ₹178 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹739.95 is trading 64.3% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Property, Plant and Equipment: ₹178 Mil
  • GF Value™: ₹2,071.36 vs. price of ₹739.95 (64.3% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
61GF Score

Get the complete analysis for NSE:REMUS

Property, Plant and Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹739.95
Price
₹2,071.36
GF Value